3,3 '-Disubstituted 5,5 '-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity
Lian Xue, Da-Hua Shi, Jitendra R Harjani, Fei Huang, Julia G Beveridge, Tamir Dingjan, Kung Ban, Sarah Diab, Sandra Duffy, Leonardo Lucantoni, Sabine Fletcher, Francis CK Chiu, Scott Blundell, Katherine Ellis, Stuart A Ralph, Grennady Wirjanata, Silvia Teguh, Rintis Noviyanti, Marina Chavchich, Darren Creek Show all
Journal of Medicinal Chemistry | AMER CHEMICAL SOC | Published : 2019
Awarded by National Health and Medical Research Council of Australia (NHMRC)
The National Health and Medical Research Council of Australia (NHMRC) is thanked for Research Support (no. 1102147) and Fellowship support for J.B. (2012-2016 Senior Research Fellowship no. 1020411, 2017, Principal Research Fellowship no. 1117602). Acknowledged is Australian Federal Government Education Investment Fund Super Science Initiative and the Victorian State Government, Victoria Science Agenda Investment Fund for infrastructure support, and the facilities and the scientific and technical assistance of the Australian Translational Medicinal Chemistry Facility (ATMCF), Monash Institute of Pharmaceutical Sciences (MIPS). ATMCF is supported by Therapeutic Innovation Australia (TIA). TIA is supported by the Australian Government through the National Collaborative Research Infrastructure Strategy (NCRIS) program. We are grateful to Kerryn Rowcliffe for technical support in in vitro drug susceptibility testing and thank the Australian Red Cross Blood Service for the provision of human blood and sera for in vitro cultivation of P. falciparum lines at ADFMIDI. We also thank Donna MacKenzie, Geoffrey Birrell, and Stephen McLeod -Robertson for the in vivo efficacy testing of 6k in the P. berghei rodent model. The views expressed in this article are those of the authors and do not necessarily reflect those of the Australian Defence Force Joint Health Command or any extant Australian Defence Force policy.